The new Class I recall includes nearly 27,000 devices that could potentially experience a harmful defect during use. 

When TAVR patients present with moderate or greater tricuspid regurgitation, it could impact the care team's treatment strategy of choice.

Use of the drug more than doubles a person's risk of dying from heart disease, according to a new analysis of 24 different studies. In a separate editorial, two physicians shared their concerns and highlighted the importance of discussing these risks with patients.

Nuclear medicine operations may soon enjoy steadier flows of certain in-demand radioisotopes. If so, much credit will go to companies that had the strategic sense to collaborate with each other. 

A report from the Guardian details how the VA removed language protecting patients from discrimination based on political affiliation and lifestyle. The department denies that there has been any actual change in policy.

Nonprofit Ascension Health announced its purchase of Amsurg, adding 250 outpatient surgery centers to its expanding portfolio. The Catholic-based hospital group said the move will allow it to focus more on community-based care by keeping more patient referrals in-house.

POCUS could represent a quick, easy and affordable way to detect signs of insulin resistance before it progresses into diabetes, researchers suggest.

There is an increased risk that these devices will not provide audible alerts for low or high blood glucose levels. The FDA has ruled that this is a Class I recall, highlighting the safety risks associated with missed alerts.